Skip to main content

Toviaz FDA Approval History

FDA Approved: Yes (First approved October 31, 2008)
Brand name: Toviaz
Generic name: fesoterodine fumarate
Dosage form: Extended Release Tablets
Company: Pfizer Inc.
Treatment for: Urinary Frequency

Toviaz (fesoterodine fumarate) is a competitive muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Development timeline for Toviaz

Oct 31, 2008Approval Pfizer's Toviaz (fesoterodine fumarate) Receives FDA Approval for the Treatment of Overactive Bladder

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.